77.84 0.00 (0.00%)
After hours: 5:15PM EST
|Bid||77.84 x 800|
|Ask||77.89 x 3000|
|Day's range||77.70 - 80.89|
|52-week range||62.48 - 110.37|
|Beta (5Y monthly)||0.77|
|PE ratio (TTM)||N/A|
|Earnings date||03 May 2021 - 07 May 2021|
|Forward dividend & yield||N/A (N/A)|
|1y target est||105.38|
The biotech sector was in focus last week with regulatory and pipeline updates from quite a few companies like Regeneron (REGN), Vir (VIR) and KemPharm, Inc. (KMPH).
Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ:INCY) announced today top-line results from BRAVE-AA2, a Phase 3 study evaluating the efficacy and safety of once-daily baricitinib 2-mg and 4-mg in adults with severe alopecia areata (AA). Both doses of baricitinib met the primary efficacy endpoint at Week 36, demonstrating a statistically significant improvement in scalp hair regrowth compared to those randomized to placebo. AA is an autoimmune disease that causes patchy hair loss on the scalp, face and sometimes on other areas of the body that can progress. Baricitinib has received Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA) for the treatment of AA. This classification aims to expedite the development and review of drugs that are intended to treat a serious condition when preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over already available therapies on a clinically significant endpoint(s). There are currently no FDA-approved treatments for AA.
Incyte Announces Validation by the EMA of Marketing Authorization Application for Retifanlimab as a Treatment for Squamous Cell Anal Carcinoma (SCAC)